8月5日，中生北控生物科技（股票代码：08247.HK）宣布，计划收购上海江慈70.3%的股权。
根据公告，该公司将分两步完成交易。首先，以280万股H股作为支付对价，每股作价3.2港元，此部分对应上海江慈10%的股权，价值约770万元人民币。接着，再通过现金出资1.563亿元人民币，认购上海江慈67%的股权。
整个交易的总对价约为1.64亿元人民币，折合港元约1.903亿。完成收购后，公司将持有上海江慈70.3%的股权。
具体交易细节与后续进展，请继续关注公司公告。
8月5日，中生北控生物科技（股票代码：08247.HK）宣布，计划收购上海江慈70.3%的股权。
根据公告，该公司将分两步完成交易。首先，以280万股H股作为支付对价，每股作价3.2港元，此部分对应上海江慈10%的股权，价值约770万元人民币。接着，再通过现金出资1.563亿元人民币，认购上海江慈67%的股权。
整个交易的总对价约为1.64亿元人民币，折合港元约1.903亿。完成收购后，公司将持有上海江慈70.3%的股权。
具体交易细节与后续进展，请继续关注公司公告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.